EMERGENT BIOSOLUTIONS INC. Proceeds from Long-Term Debt Issued
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Long-Term Debt Issued of $798.00 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2019-02-22
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of long-term debt for the quarter ending 2016-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of long-term debt for the quarter ending 2015-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of long-term debt for fiscal 2018 was $798.00M.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of long-term debt for fiscal 2017 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of long-term debt for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. proceeds from issuance of long-term debt for fiscal 2015 was $2.00M, a 100.00% increase from fiscal 2014.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|
| 2018-12-31 | $798.00M 10-K · filed 2019-02-22 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-02-22 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 | |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $2.00M 10-K · filed 2018-02-23 | |
| 2015-09-30 | $2.00M 10-Q · filed 2016-11-09 | ||
| 2014-12-31 | $1.00M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |